BackARS Pharmaceuticals Overview

ARS Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for SPRY.

Quarterly SG&A Expenses

$72.20M
↑ 75.66% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$261.22M
↑ 149.22% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin